- Home
- OBT vs IPHA Comparison
OBT vs IPHA Comparison
Compare OBT & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBT
- IPHA
- Stock Information
- Founded
- OBT 1892
- IPHA 1999
- Country
- OBT United States
- IPHA France
- Employees
- OBT N/A
- IPHA N/A
- Industry
- OBT Major Banks
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- OBT Finance
- IPHA Health Care
- Exchange
- OBT Nasdaq
- IPHA Nasdaq
- Market Cap
- OBT 310.4M
- IPHA 175.5M
- IPO Year
- OBT N/A
- IPHA 2019
- Fundamental
- Price
- OBT $57.51
- IPHA $2.00
- Analyst Decision
- OBT Buy
- IPHA Strong Buy
- Analyst Count
- OBT 2
- IPHA 1
- Target Price
- OBT $60.00
- IPHA $11.50
- AVG Volume (30 Days)
- OBT 16.0K
- IPHA 9.4K
- Earning Date
- OBT 10-28-2024
- IPHA 09-12-2024
- Dividend Yield
- OBT 1.61%
- IPHA N/A
- EPS Growth
- OBT 18.47
- IPHA N/A
- EPS
- OBT 6.15
- IPHA N/A
- Revenue
- OBT $102,957,000.00
- IPHA $36,202,722.00
- Revenue This Year
- OBT N/A
- IPHA N/A
- Revenue Next Year
- OBT $6.15
- IPHA $102.87
- P/E Ratio
- OBT $9.33
- IPHA N/A
- Revenue Growth
- OBT 13.39
- IPHA N/A
- 52 Week Low
- OBT $39.71
- IPHA $1.81
- 52 Week High
- OBT $64.01
- IPHA $3.15
- Technical
- Relative Strength Index (RSI)
- OBT 52.79
- IPHA 41.71
- Support Level
- OBT $54.83
- IPHA $1.94
- Resistance Level
- OBT $56.76
- IPHA $2.10
- Average True Range (ATR)
- OBT 1.62
- IPHA 0.08
- MACD
- OBT 0.11
- IPHA -0.01
- Stochastic Oscillator
- OBT 56.69
- IPHA 16.00
About OBT Orange County Bancorp Inc.
Orange County Bancorp Inc provides banking services. Its services include personal banking services such as personal loans, personal savings, business loans, business savings, and Internet banking among others. The company provides commercial and consumer banking services to individuals, small businesses, and local municipal governments as well as trust and investment services through the Bank and HVIA. Its segment includes banking and wealth management. The company generates maximum revenue from the banking segment.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.